Swiss TPH researchers testing compounds in vitro against malaria parasites. (Photo: Joachim Pelikan)
On World Malaria Day 2019, Swiss organizations look back on a long history of successful public-private collaboration for new malaria medicines. Switzerland's leading role in the fight against malaria was strengthened with the establishment of the first product development partnership 20 years ago. Swiss collaborations have brought forward 11 new approved anti-malarial medicines and helped to save more than 1.9 million lives globally. On 24 April, Swiss authorities, the Swiss Malaria Group, global health organizations and the diplomatic community meet in Geneva to celebrate two decades of successful Swiss collaborations and to discuss the way forward in malaria elimination. A long history of Swiss leadership in antimalarial research Switzerland has a long history of leadership and engagement in the fight against malaria. High-level malaria research has been carried out for over 70 years at Swiss TPH and later other Swiss universities and pharmaceutical companies. Today, thanks to Swiss contributions, 11 new antimalarials, brought forward by Medicines for Malaria Venture (MMV) and partners, have been pre-qualified by the World Health Organization (WHO) or approved by stringent regulatory authorities.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
